Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 12/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509540 | 0.90 | RAB9A (0.47) | RAB9ANPC1HTR3AKDM4EALDH1A1 | |
| SCHEMBL4963489 | 0.87 | CARM1 (0.49) | CARM1HDAC6 | |
| SCHEMBL4964920 | 0.84 | CARM1 (0.48) | CARM1HDAC6 | |
| SCHEMBL12834549 | 0.81 | RAB9A (0.47) | RAB9ANPC1HTR3AKDM4EALDH1A1 | |
| SCHEMBL4962190 | 0.81 | HDAC6 (0.51) | CARM1HDAC6 | |
| SCHEMBL4964897 | 0.80 | CARM1 (0.51) | CARM1HDAC6 | |
| SCHEMBL4963154 | 0.79 | HDAC6 (0.60) | CARM1HDAC6 | |
| SCHEMBL4964947 | 0.79 | GSK3B (0.51) | CARM1HDAC6 | |
| SCHEMBL4963532 | 0.78 | HDAC6 (0.50) | CARM1HDAC6 | |
| SCHEMBL4965539 | 0.78 | HDAC6 (0.61) | CARM1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | RAB9A 2622/4885NPC1 2983/4885HTR3A 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.